5Rabe KF, Hurd S, Anzueto A, et aL Global strategy for the diagno- sis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med, 2007,176(10) :532-555.
6Job FMVB,Niels HC,Thys VD M,et al.Clinical and economic impact of non-adherence in COPD: A systematic review [J]. Respir Med,2014,108(1):103-113.
7Andrea P, Sean M,Henry B,et al.Albuterol and levalbuterol use and spending in medicare beneficiaries with chronic obstructive pulmonary disease[J].Am J Geriat Pharmacother,2010,8(6):571-582.
8ZuWallack R,De Salvo MC,Kaelin T, et al.Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat: inhaler versus MDI [J].Respir Med,2010,104(8):1179-1188.
